Entropy Technologies LP Has $2.27 Million Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Entropy Technologies LP lifted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 69.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 5,500 shares of the company's stock after purchasing an additional 2,259 shares during the quarter. Entropy Technologies LP's holdings in IDEXX Laboratories were worth $2,274,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. FSA Wealth Management LLC acquired a new stake in IDEXX Laboratories in the third quarter valued at about $25,000. E Fund Management Hong Kong Co. Ltd. boosted its stake in IDEXX Laboratories by 5,700.0% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company's stock valued at $29,000 after buying an additional 57 shares in the last quarter. Retirement Wealth Solutions LLC acquired a new stake in IDEXX Laboratories in the fourth quarter valued at about $31,000. Mowery & Schoenfeld Wealth Management LLC boosted its stake in IDEXX Laboratories by 750.0% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company's stock valued at $34,000 after buying an additional 60 shares in the last quarter. Finally, Ashton Thomas Securities LLC acquired a new stake in IDEXX Laboratories in the third quarter valued at about $37,000. 87.84% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at IDEXX Laboratories

In other news, Director M Anne Szostak sold 3,000 shares of the firm's stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the transaction, the director now directly owns 3,061 shares in the company, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Sophie V. Vandebroek sold 344 shares of the firm's stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the sale, the director now directly owns 905 shares of the company's stock, valued at $380,498.20. This represents a 27.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 13,330 shares of company stock worth $6,161,276 over the last ninety days. 2.11% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on IDXX shares. Morgan Stanley reduced their price objective on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 29th. Bank of America increased their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research report on Tuesday, February 4th. Leerink Partners started coverage on IDEXX Laboratories in a research report on Monday, December 2nd. They issued an "outperform" rating and a $500.00 target price for the company. Barclays increased their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research report on Tuesday, February 4th. Finally, Piper Sandler increased their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research report on Monday. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, IDEXX Laboratories has a consensus rating of "Moderate Buy" and an average price target of $533.75.

IDEXX Laboratories Trading Up 0.5 %

Shares of IDXX traded up $2.41 during mid-day trading on Thursday, reaching $459.76. 601,058 shares of the company were exchanged, compared to its average volume of 718,152. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $583.39. The company has a debt-to-equity ratio of 0.28, a quick ratio of 1.03 and a current ratio of 1.31. The stock has a market capitalization of $37.65 billion, a PE ratio of 43.09, a PEG ratio of 3.47 and a beta of 1.37. The business has a 50 day simple moving average of $430.12 and a two-hundred day simple moving average of $453.26.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.